UK regulators act on CBD: MHRA draws a hard line, whereas FSA softens its stance

The UK Medicines and Healthcare Products Regulatory Agency (MHRA) has drawn a clear line on CBD’s medical claims. Meanwhile, the Food Standards Agency (FSA) seems now to have softened its stance on the allowable levels of THC in CBD novel food products after it said it would have treated THC like a contaminant and its permitted levels in CBD products would have been below Home Office drug law levels.

The MHRA stated that if a company markets a product containing cannabidiol (CBD) and claims that it is medicinally effective, it will fall within the definition of a medicine under the Human Medicines Regulations 2012 and must hold marketing authorisation.

Read full article
I'm already a subscriber

Antonia Di Lorenzo

Newsdesk editor/EU lead reporter
Antonia is a member of the editorial team and holds a masters degree in Law from the University of Naples Federico II, Italy. She moved in 2013 to London, where she completed a postgraduate course at the London School of Journalism. In the UK, she worked as a news reporter for a financial newswire and a magazine before moving to Barcelona in 2019.

Our Key Benefits

The global cannabis market is in an opaque regulatory environment that requires professionals to be on top of industry developments to make informed decisions and optimise their strategy.

CannIntelligence provides organisations with leading market and regulatory data analysis to anticipate and understand market developments globally and the impact of regulatory changes to the business.

  • Stay informed of any legal and market change in the sector that impacts your organisation
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization